ABSI
ABSI
Positions held
Your positionsABSI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?
2026-09-24 · Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
2026-09-24 · Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
2026-09-22 · Absci (ABSI) Stock Looks Expensive Against Its Book Value
2026-09-21 · Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
2026-09-12 · Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
2026-09-03 · AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
2026-09-01 · Absci to Participate in Upcoming Investor Conferences
2026-08-31 · Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
2026-08-19 · Absci (ABSI) Q2 2026 Earnings Call Transcript
2026-08-18 · AMD’s $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
2026-08-18 · The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
Price (daily)
Full chart · RSI · MACD · patterns